Dr. Renteria’s primary areas of focus are the Hematologic Malignancies and Stem Cell Transplantation. She has clinical and research interest in Graft Versus Host Disease (GVHD). She is the Principal Investigator of two multicenter trials investing GVHD in patients undergoing allogeneic HSCT: the MAGIC (Mount Sinai Acute GVHD International Consortium) trial evaluating the stratification of GVHD through plasma biomarkers predicting treatment response, and the BMT CTN 1202 trial of biomarkers evaluating the GVHD complications. She also is a co-investigator on several studies focused on transplantation and the Hematologic Malignancies.